MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2016 International Congress

    A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

    K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

    Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
  • 2016 International Congress

    Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

    R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)

    Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…
  • 2016 International Congress

    Body position during sleep in patients with Parkinson’s disease (PD): A sensor-based analysis

    J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

    Objective: To identify the body position during sleep in PD patients in comparison to their spouses by using multisite wearable inertial sensors. Background: Nocturnal hypokinesia…
  • 2016 International Congress

    STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

    T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

    Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
  • 2016 International Congress

    Deep brain stimulation effect on the quality of life of individuals with Parkinson’s disease

    A. Ayres, M. Ghisi, A.M. Freiry, B.S.F. Oliveira, A.F.S. Schuch, C.R.M. Rieder, M.R. Olchik (Porto Alegre, Brazil)

    Objective: To identify the perception of QOL in individuals with PD pre and post DBS. Background: The DBS is one type of effective treatment in…
  • 2016 International Congress

    Spinal cord stimulation improves freezing of gait in Parkinson’s disease in chronic implanted stn-dbs patients: A case report

    C.O. Souza, C.P. Souza, A.L. Pardini, D. Boari, L.A. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)

    Objective: The aim of our study was to evaluate further the potential role of spinal cord stimulation (SCS) as a treatment for gait disturbances and…
  • 2016 International Congress

    Pisa syndrome in Parkinson’s disease effectively treated with subthalmic deep brain stimulation: Case report

    C.A. Artusi, A. Romagnolo, M. Zibetti, M.G. Rizzone, A. Merola, F. Dematteis, M. Lanotte, L. Lopiano (Torino, Italy)

    Objective: To report the case of a 67-year-old Parkinsonian patient with significant and disabling Pisa syndrome (PS) successfully treated with subthalamic nucleus deep brain stimulation…
  • 2016 International Congress

    Recharge frequency is not driven by therapy power usage in patients implanted with rechargeable deep brain stimulation systems

    T. Weaver, P. Konrad, L. Timmerman, G. Molnar, K. Stromberg (Minneapolis, MN, USA)

    Objective: To explore the relationship between recharge frequency and therapy power usage in patients with rechargeable deep brain stimulation (DBS) devices. Background: Advancements in DBS…
  • 2016 International Congress

    Non-motor symptoms in progressive supranuclear palsy

    R. Ou, W. Song, Q. Wei, K. Chen, B. Cao, Y. Hou, B. Zhao, H. Shang (Chengdu, People's Republic of China)

    Objective: To explore the clinical correlates of Non-motor symptoms (NMS) in progressive supranuclear palsy (PSP) and their differences from healthy aging and Parkinson's disease (PD).…
  • 2016 International Congress

    A case series of sigmoid volvulus in Parkinson’s disease

    K. Khalid, A. McColl, M. Gosney, A.K. Chatterjee (Reading, United Kingdom)

    Objective: To study the outcomes of patients with Parkinson's disease (PD) who were admitted with a diagnosis of sigmoid volvulus. Background: Constipation is a common…
  • « Previous Page
  • 1
  • …
  • 334
  • 335
  • 336
  • 337
  • 338
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley